SCHEMBL365852

SCHEMBL365852

CCOC(=O)C(F)P(=O)(OCC)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
POLB P06746 1/20 0.38
ALDH1A1 P00352 3/20 0.37
TSHR P16473 2/20 0.37
GAA P10253 2/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
CYP2D6 P10635 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17249688 0.90 ALDH1A1 (0.39) CYP3A4CYP2C9CYP2C19POLBALDH1A1
SCHEMBL16761024 0.86 CYP3A4 (0.41) CYP3A4CYP2C9CYP2C19POLBALDH1A1
SCHEMBL16761022 0.83 ALDH1A1 (0.42) CYP3A4CYP2C9CYP2C19POLBALDH1A1
SCHEMBL13469072 0.82 ACHE (0.38) CYP3A4CYP2C9CYP2C19POLBALDH1A1
SCHEMBL16761019 0.82 TSHR (0.37) CYP3A4CYP2C9CYP2C19POLBTSHR
SCHEMBL16979607 0.81 CYP3A4 (0.38) CYP3A4CYP2C9CYP2C19POLBALDH1A1
SCHEMBL2992966 0.81 CYP3A4 (0.40) CYP3A4CYP2C9CYP2C19POLBTSHR
SCHEMBL2646513 0.81 POLB (0.43) CYP3A4CYP2C9CYP2C19POLBTSHR
SCHEMBL10987006 0.80 ALDH1A1 (0.34) CYP3A4CYP2C9CYP2C19POLBALDH1A1
SCHEMBL16978355 0.80 CYP3A4 (0.34) CYP3A4CYP2C9CYP2C19POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 815 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025264651-A1 ELECTROLYTE AND LITHIUM ION BATTERIES MADE THEREWITH WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) 2025-12-26 WO claimed
US-20180198166-A1 NON-AQUEOUS ELECTROLYTE AND POWER STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2018-07-12 US claimed
EP-2882030-B1 NON-AQUEOUS ELECTROLYTE AND ENERGY STORAGE DEVICE USING THE SAME UBE INDUSTRIES (JP) 2017-06-21 EP claimed
US-20150221985-A1 NON-AQUEOUS ELECTROLYTE AND POWER STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD. (JP) 2015-08-06 US claimed
EP-2882030-A1 NON-AQUEOUS ELECTROLYTE AND POWER STORAGE DEVICE USING SAME Ube Industries, Ltd. (JP) 2015-06-10 EP claimed
US-8795884-B2 Nonaqueous secondary battery and electronic device HITACHI MAXELL, LTD. (JP) 2014-08-05 US claimed
US-8574757-B2 Nonaqueous electrolytic solution and nonaqueous electrolyte battery MITSUBISHI CHEMICAL CORPORATION (JP) 2013-11-05 US claimed
US-20120264011-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-10-18 US claimed
US-20110052980-A1 NONAQUEOUS SECONDARY BATTERY AND ELECTRONIC DEVICE MAXELL, LTD. (JP) 2011-03-03 US claimed
EP-1409512-A1 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE Aventis Pharma S.A. (FR) 2004-04-21 EP claimed
EP-0946492-B1 NOVEL 2-FLUOROACRYLIC ACID DERIVATIVES, NOVEL MIXTURES OF HERBICIDES AND ANTIDOTES AND THE USE THEREOF BAYER CROPSCIENCE GMBH (DE) 2003-06-18 EP claimed
US-6413951-B2 ENZYME INHIBITOR AVENTIS PHARMACEUTICALS, INC. 2002-07-02 US claimed
US-20020019548-A1 20-Fluoro-17(20)-vinyl steroids AVENTIS PHARMA S.A. (FR) 2002-02-14 US claimed
WO-2002000681-A1 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE AVENTIS PHARMA S.A. (FR) 2002-01-03 WO claimed
US-5972839-A MIXTURE WITH PLANT SAFENING AGENT HOECHST SCHERING AGREVO GMBH (DE) 1999-10-26 US claimed
EP-4743465-A1 BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-20 EP disclosed
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2026-05-14 US disclosed
US-4171318-A 9-(SUBSTITUTED PHENYL), 4 OR 6-FLUORO-RETINOIC ACID DERIVATIVES, ANTITUMOR AND ANTIACNE AGENTS HOFFMANN-LA ROCHE INC. (US) 1979-10-16 US disclosed
US-4169100-A FLUORO AND TRIFLUOROMETHYL SUBSTITUTED 9-(4-ALKOXY-2,3,6-TRIALKYLPHENYL)-2,4,6,8-NONATETRAENOIC ACIDS, ESTERS AND AMIDES, ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1979-09-25 US disclosed
US-4137246-A ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, IRF3, CGAS CYP3A4 4593/4885CYP2C9 4756/4885CYP2C19 4843/4885
US-20020019548-A1 20-Fluoro-17(20)-vinyl steroids CYP17A1, HSD17B11, HSD3B1 CYP3A4 167/4885CYP2C9 158/4885CYP2C19 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.